Research Analysts’ Recent Ratings Changes for Tilray Brands (TLRY)

Several brokerages have updated their recommendations and price targets on shares of Tilray Brands (NASDAQ: TLRY) in the last few weeks:

• 1/27/2026 – Tilray Brands is now covered by analysts at Canaccord Genuity Group Inc.. They set a “hold” rating on the stock.
• 1/21/2026 – Tilray Brands had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – Tilray Brands had its price target lowered by analysts at Roth Mkm from $20.00 to $10.00. They now have a “neutral” rating on the stock.
• 1/13/2026 – Tilray Brands was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 12/10/2025 – Tilray Brands was upgraded by analysts at Atb Cap Markets from a “strong sell” rating to a “hold” rating.

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.